Video: Every Case Tells a Story| Webinar: ACR/CHEST ILD Guidelines in Practice

An official publication of the ACR and the ARP serving rheumatologists and rheumatology professionals

  • Conditions
    • Axial Spondyloarthritis
    • Gout and Crystalline Arthritis
    • Myositis
    • Osteoarthritis and Bone Disorders
    • Pain Syndromes
    • Pediatric Conditions
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Sjögren’s Disease
    • Systemic Lupus Erythematosus
    • Systemic Sclerosis
    • Vasculitis
    • Other Rheumatic Conditions
  • FocusRheum
    • ANCA-Associated Vasculitis
    • Axial Spondyloarthritis
    • Gout
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Systemic Lupus Erythematosus
  • Guidance
    • Clinical Criteria/Guidelines
    • Ethics
    • Legal Updates
    • Legislation & Advocacy
    • Meeting Reports
      • ACR Convergence
      • Other ACR meetings
      • EULAR/Other
    • Research Rheum
  • Drug Updates
    • Analgesics
    • Biologics/DMARDs
  • Practice Support
    • Billing/Coding
    • EMRs
    • Facility
    • Insurance
    • QA/QI
    • Technology
    • Workforce
  • Opinion
    • Patient Perspective
    • Profiles
    • Rheuminations
      • Video
    • Speak Out Rheum
  • Career
    • ACR ExamRheum
    • Awards
    • Career Development
  • ACR
    • ACR Home
    • ACR Convergence
    • ACR Guidelines
    • Journals
      • ACR Open Rheumatology
      • Arthritis & Rheumatology
      • Arthritis Care & Research
    • From the College
    • Events/CME
    • President’s Perspective
  • Search

Adding Prednisone to Methotrexate May Be Helpful in Early RA

Marilynn Larkin  |  May 23, 2017

“However,” he adds, “two important caveats have to be mentioned. First, the study findings can also be explained by other treatments—known and unknown—during the post-trial follow-up and not necessarily from prednisone. Second, although better radiographic outcomes were seen with the use of prednisone, we do not know whether patients were actually doing better in the absence of disease-specific quality of life measure.”


References

ad goes here:advert-1
ADVERTISEMENT
SCROLL TO CONTINUE
  1. Safy M, Jacobs J, IJff ND, et al. Long-term outcome is better when a methotrexate-based treatment strategy is combined with 10 mg prednisone daily: Follow-up after the second Computer-Assisted Management in Early Rheumatoid Arthritis trial. Ann Rheum Dis. 2017 Apr 27. pii: annrheumdis-2016-210647. doi: 10.1136/annrheumdis-2016-210647. [Epub ahead of print]
  2. Bakker MF, Jacobs JW, Welsing PM, et al. Low-dose prednisone inclusion in a methotrexate-based, tight control strategy for early rheumatoid arthritis: A randomized trial. Ann Intern Med. 2012 Mar 6;156(5):329-39. doi: 10.7326/0003-4819-156-5-201203060-00004.

Page: 1 2 | Single Page
Share: 

Filed under:ConditionsRheumatoid Arthritis Tagged with:early arthritisMethotrexateprednisoneRheumatoid Arthritis (RA)

Related Articles

    Is Predisone 3 mg/day an Appropriate Dose for Patients with Rheumatoid Arthritis?

    April 1, 2013

     Long-term, low-dose prednisone at less than 5 mg/day appears tolerable and effective for many patients with rheumatoid arthritis (RA)

    Chronotherapy with Glucorticoids in Rheumatoid Arthritis

    January 17, 2011

    Time is of the essence in balancing risks and benefits

    Old Drugs Can Learn New Tricks

    November 1, 2011

    Methotrexate and its mechanism of action

    Almost Half of Patients with RA Experience Flare after Glucocorticoid Discontinuation

    October 25, 2022

    In a post hoc analysis of two clinical trials, Maassen et al. demonstrated that 40% of patients with early RA or undifferentiated arthritis experienced disease flare after primary glucocorticoid discontinuation despite background treatment with conventional synthetic DMARDs.

  • About Us
  • Meet the Editors
  • Issue Archives
  • Contribute
  • Advertise
  • Contact Us
  • Copyright © 2025 by John Wiley & Sons, Inc. All rights reserved, including rights for text and data mining and training of artificial technologies or similar technologies. ISSN 1931-3268 (print). ISSN 1931-3209 (online).
  • DEI Statement
  • Privacy Policy
  • Terms of Use
  • Cookie Preferences